Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Machine learning–based detection model for leukemia cells in peripheral blood smears using YOLOv11-large

Johan Diaz, Arunima Deb, Alexandra Lyubimova et al. Nov 03, 2025 pp. 6123-6123 10.1182/blood-2025-6123

Abstract Background: Identification of blood cell types is crucial for diagnosing and managing hematological diseases such as lymphoma and l...

N6-methyladenosine (m6A) RNA modification is required to final plasma cell differentiation

Morgane Thomas, Elvira Garcia De Paco, Matthieu Angles et al. Nov 03, 2025 pp. 5704-5704 10.1182/blood-2025-5704

Abstract Plasma cells are highly specialized cells representing the end stage of B cell differentiation. They play an important role in humo...

An mRNA-based cytomegalovirus vaccine induces robust T-cell immune responses in cytomegalovirus-seropositive adults who have undergone allogeneic hematopoietic cell transplantation

Nicolas Issa, Jessica Little, Jennifer Husson et al. Nov 03, 2025 pp. 6007-6007 10.1182/blood-2025-6007

Abstract Background: Cytomegalovirus (CMV) establishes lifelong latency and is an important risk factor for increased morbidity and mortalit...

Efficacy and safety of isa-vrd in elderly patients with or without frailty criteria: Pooled analysis of imroz and phase 1b studies in newly diagnosed multiple myeloma patients

Enrique Ocio, Aurore Perrot, Jesus San-Miguel et al. Nov 03, 2025 pp. 2267-2267 10.1182/blood-2025-2267

Abstract Introduction: In the phase 3 IMROZ study (NCT03319667), isatuximab (Isa) given intravenously (IV) with bortezomib, lenalidomide and...

ENO1 promotes Acute Myeloid Leukemia progression through SCD1-mediated lipid metabolism reprogramming

Yijun Wu, Shaoyan Hu, Li Gao et al. Nov 03, 2025 pp. 1471-1471 10.1182/blood-2025-1471

Abstract Enhanced glycolysis and aberrant hyperactivation of glycolytic enzymes collectively contributes to tumor progression and chemoresis...

Lipid uptake via FATP2 enhances CAR-t therapy resistance in B-cell acute lymphoblastic leukemia

Clarissa Garcia, Kaylyn Lyons, Julian Grandvallet Contreras et al. Nov 03, 2025 pp. 325-325 10.1182/blood-2025-325

Abstract Chimeric Antigen Receptor T cell (CAR-T) therapy is highly effective for treating relapsed/refractory B-cell acute lymphoblastic le...

Repertoire of driver events in coding and non-coding regions identified by whole-genome sequencing of myeloid neoplasms

Koji Okazaki, Ryunosuke Saiki, Yotaro Ochi et al. Nov 03, 2025 pp. 1450-1450 10.1182/blood-2025-1450

Abstract Introduction: During the past two decades, our knowledge about the molecular pathogenesis of myeloid neoplasms (MNs), including acu...

R2* MRI in evaluation of hepatic iron overload and its correlation with serum ferritin in transfusion-dependent beta-thalassemia

Anannya Bhakat, Gaurav Chhabra, Sonali Mohapatra et al. Nov 03, 2025 pp. 6478-6478 10.1182/blood-2025-6478

Abstract Introduction: For patients with transfusion-dependent thalassemia (TDT), regular blood transfusions are a double-edged sword. While...

Individualizing apheresis processing volumes using a predictive algorithm: Analysis of the CAR T-cell collection protocol utilized in ACIT001/EXC002, a phase lb/ll trial of decentralized production of CAR T-cells for treatment of relapsed/refractory aggressive NHL and ALL

Jennifer Croden, Zackariah Breckenridge, Charles Yin et al. Nov 03, 2025 pp. 5962-5962 10.1182/blood-2025-5962

Abstract Introduction: Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment landscape for relapsed/refractory (R/R)...

Sequential BCMA- and GPRC5D-targeted bispecific antibody therapy in multiple myeloma: Real-world outcomes and first report of dual bispecific antibody-refractory patients

Darren Pan, Jihong Song, Eva Duvalyn et al. Nov 03, 2025 pp. 5760-5760 10.1182/blood-2025-5760

Abstract Introduction: BCMA and GPRC5D bispecific antibodies (BsAbs) are indispensable therapies for relapsed/refractory multiple myeloma (R...

Prospective clinical validation of MAC-scoring as an affordable, real-time biomarker for HMA/venetoclax response in AML

Simon Renders, Alexander Waclawiczek, Ricarda Schwab et al. Nov 03, 2025 pp. 3493-3493 10.1182/blood-2025-3493

Abstract The treatment of acute myeloid leukemia (AML) has been transformed by incorporating hypomethylating agents (HMA) like 5-Azacytidine...

MSC regulates the function of neutrophils through mitochondrial transmission to treat early pulmonary fibrosis

Rongjia Zhu, Yunfei Ji, Wen-Xuan Huo et al. Nov 03, 2025 pp. 1218-1218 10.1182/blood-2025-1218

Abstract Mesenchymal stem cells (MSCs) are a type of adult stem cells with immunomodulatory properties. Recently, due to their safety and ef...

Association of socioeconomic indicators with survival in chronic myeloid leukemia: A retrospective analysis

Hadil Zureigat, Emily Zabor, Kristel Geyer et al. Nov 03, 2025 pp. 4636-4636 10.1182/blood-2025-4636

Abstract Background Tyrosine kinase inhibitors (TKIs) have improved outcomes of patients (pts) with chronic myeloid leukemia (CML). However,...

Measurable residual disease (MRD) assessment as an early end point oftreatment efficacy in acute myeloid leukemia (AML): A pethema studyof 2,623 patients (Pts) treated with intensive therapy

Bruno Paiva, Leire Burgos, Carmen González et al. Nov 03, 2025 pp. 5293-5293 10.1182/blood-2025-5293

Abstract Background: Despite advances in treatment of AML pts considered fit for intensive therapy, significant unmet medical needs remain....

Long-term clinical outcomes from the smart start trial: Rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma

Eduardo Edelman Saul, Karan Chohan, Richard Davis et al. Nov 03, 2025 pp. 3691-3691 10.1182/blood-2025-3691

Abstract Background Approximately 30-40% of patients (pts) with diffuse large B-cell lymphoma (DLBCL) develop relapsed or refractory (r/r) di...

Etoposide + cytarabine + pegfilgrastim vs cyclophosphamide + granulocyte colony-stimulating factor for stem-cell mobilization in patients with multiple myeloma: A phase III trial

Peipei Ye, Renzhi Pei, Lihong Shou et al. Nov 03, 2025 pp. 5960-5960 10.1182/blood-2025-5960

Abstract Background: For multiple myeloma (MM) autologous stem cell transplantation (auto-SCT) to be successful, adequat...

Salvage whole brain radiotherapy after methotrexate failure in primary cns lymphoma

Shayla Murray, Gustav Cederquist, Kathryn Tringale et al. Nov 03, 2025 pp. 3679-3679 10.1182/blood-2025-3679

Abstract Introduction: Primary CNS lymphoma (PCNSL) is a rare and aggressive subtype of mostly B-cell non-Hodgkin lymphoma. While high-dose m...

First-in-human phase I study of HCB101, a 3.5th-generation CD47-SIRPα fc fusion protein: Cytopenia-sparing safety, broad pharmacologic window, and low-dose clinical activity in relapsed/refractory non-Hodgkin lymphoma

Abigail Yu, Wenyu Li, Zhili Zhou et al. Nov 03, 2025 pp. 3299-3299 10.1182/blood-2025-3299

Abstract Introduction: Non-Hodgkin lymphoma (NHL) comprises a heterogeneous group of lymphoproliferative malignancies arising from B, T, or n...

Incidence and risk factors for CNS relapse in adult ALL after allogeneic hematopoietic cell transplant

Catherine Le, Amy Zhang, Rutu Vyas et al. Nov 03, 2025 pp. 6038-6038 10.1182/blood-2025-6038

Abstract Introduction Relapse in the central nervous system (CNS) is a devastating outcome in acute lymphoblastic leukemia (ALL). Increasing...

primary breast lymphoma: A 10-year retrospective case series on clinical features, diagnostic imaging, and outcomes from a diverse population treated at mount sinai medical center in miami beach

Carla Romagnoli, Leily Santos-Carrion, Alexandra Lyubimova et al. Nov 03, 2025 pp. 8105-8105 10.1182/blood-2025-8105

Abstract Introduction Primary breast lymphoma (PBL) is a rare subtype of non-Hodgkin lymphoma (NHL), accounting for less...

Transfer and integration into a young adult clinic for sickle cell disease: Stay with me

Elizabeth Prince, Eboni Lance, Morgan Bifano et al. Nov 03, 2025 pp. 6220-6220 10.1182/blood-2025-6220

Abstract Introduction: Near universal survival of children with sickle cell disease (SCD) into adulthood makes transition from pediatric to...

Humanized CD19 chimeric antigen receptor (CAR) T-cell therapy for high-risk and post-CAR relapse of B-cell acute lymphoblastic leukemia

Lucy Cain, Yimei Li, Hongyan Liu et al. Nov 03, 2025 pp. 646-646 10.1182/blood-2025-646

Abstract Background CD19-directed chimeric antigen receptor T-cell (CART19) therapy has transformed the treatment landscape for relapsed/ref...

Multi-modal profiling and targeting of the tumor microenvironment in central nervous system lymphoma

Haryoon Kim, Junji Koya, Nobuyoshi Sasaki et al. Nov 03, 2025 pp. 148-148 10.1182/blood-2025-148

Abstract Primary central nervous system lymphoma (PCNSL) is a highly aggressive B-cell lymphoma confined to the CNS and associated with a po...

Risk of hepatitis B virus reactivaton in HBsAg-negative, anti-hbc-positive patients receiving rituximab: A systematic review

Rachael Principato, Roger Kou, Lauren Hui et al. Nov 03, 2025 pp. 6309-6309 10.1182/blood-2025-6309

Abstract Background Rituximab is an anti-CD20 monoclonal antibody widely used in the treatment of hematologic malignancies and autoimmune co...

Efficacy and safety of iptacopan in Chinese patients with paroxysmal nocturnal hemoglobinuria: A multicenter retrospective study

Xiaoqing Li, Zhilong Xu, Yan Guo et al. Nov 03, 2025 pp. 2893-2893 10.1182/blood-2025-2893

Abstract Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare clonal disorder caused by PIGA mutations leading to deficiency of G...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page